N/A
N=204
Evaluation of Pharmacogenetic Factors Affecting Fentanyl Requirements for Postoperative Pain Control
Pain, Postoperative
Bottom Line
View on ClinicalTrials.gov: NCT00824772 ↗Enrolled (actual)
204
Serious AEs
0.0%
Results posted
May 2013
Primary outcome: Primary: Postoperative Cumulative Fentanyl Consumption — 836 mcg
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 19+ yrs
- Sex
- Female
- Sponsor
- Inje University
- Primary completion
- Dec 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Postoperative Cumulative Fentanyl Consumption |
1028 | — |
| SECONDARY Postoperative Cumulative Fentanyl Consumption |
1028 | — |
Summary
Fentanyl is a widely used opioid analgesic. There are big interindividual variabilities in dose requirements of fentanyl for postoperative pain control. This study aims to reveal the genetic factors affecting the variable requirements of fentanyl during postoperative period.
Eligibility Criteria
Inclusion Criteria
- Patients undergoing total abdominal hysterectomy (TAH) or laparoscopy assisted vaginal hysterectomy (LAVH) under general anesthesia
- Patients who want to use intravenous patient controlled analgesia (PCA) after surgery
- ASA physical status class I, II
Exclusion Criteria
- history of drug addiction
- opioid medication within 12 hours before surgery
- previous history of opioid medication for 3 months
- neurologic disorder
- cardiac disorder
- hepatic disease
- renal disease
- respiratory disease such as COPD, asthma
- sleep apnea
- BMI > 30
- psycotic disorder
Data sourced from ClinicalTrials.gov (NCT00824772). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.